Bernd Seizinger Buys 40,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger bought 40,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average price of $0.85 per share, with a total value of $34,000.00. Following the completion of the acquisition, the director directly owned 566,991 shares of the company’s stock, valued at $481,942.35. This represents a 7.59% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Oncolytics Biotech Stock Up 27.0%

Shares of Oncolytics Biotech stock opened at $1.06 on Friday. The stock’s fifty day moving average is $0.98 and its 200-day moving average is $1.07. The firm has a market capitalization of $112.51 million, a PE ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a 12-month low of $0.33 and a 12-month high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. Analysts expect that Oncolytics Biotech Inc. will post -0.28 EPS for the current year.

Key Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech in the 3rd quarter worth approximately $535,000. Seeds Investor LLC raised its holdings in shares of Oncolytics Biotech by 17.8% in the second quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after buying an additional 33,826 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $63,000. CIBC Private Wealth Group LLC acquired a new position in Oncolytics Biotech during the 4th quarter worth $44,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at $30,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on ONCY. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Finally, HC Wainwright lifted their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.